Polymorphism in the 5′-End of the Aldose Reductase Gene Is Strongly Associated With the Development of Diabetic Nephropathy in Type I Diabetes
暂无分享,去创建一个
[1] N. Hotta,et al. [Risk factors for the development of diabetic complications]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.
[2] M. Hibberd,et al. Chromosome 7q35 and susceptibility to diabetic microvascular complications. , 1996, Journal of diabetes and its complications.
[3] A. Barnett,et al. Nephropathy in Type 1 Diabetes: the Role of Genetic Factors , 1995, Diabetic medicine : a journal of the British Diabetic Association.
[4] K. Lam,et al. An (A-C)n Dinucleotide Repeat Polymorphic Marker at the 5′ End of the Aldose Reductase Gene Is Associated With Early-Onset Diabetic Retinopathy in NIDDM Patients , 1995, Diabetes.
[5] K. Lam,et al. An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. , 1995, Diabetes.
[6] E. Boel,et al. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? , 1995, Journal of diabetes and its complications.
[7] B. Martin,et al. Cloning, genomic organization, and osmotic response of the aldose reductase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Cotter,et al. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. , 1994, Diabetes/metabolism reviews.
[9] R. Frank. The Aldose Reductase Controversy , 1994, Diabetes.
[10] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[11] T. Mohandas,et al. Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11, and 13. , 1993, Genomics.
[12] K. Bohren,et al. Characterization of the human aldose reductase gene promoter. , 1993, The Journal of biological chemistry.
[13] P. Tesauro,et al. Effect of Aldose Reductase Inhibitor (Tolrestat) on Urinary Albumin Excretion Rate and Glomerular Filtration Rate in IDDM Subjects With Nephropathy , 1993, Diabetes Care.
[14] P. Raskin,et al. Association of Erythrocyte Aldose Reductase Activity with Diabetic Complications in Type 1 Diabetes Mellitus , 1993, Diabetic medicine : a journal of the British Diabetic Association.
[15] M. Mcdaniel,et al. Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.
[16] P. Raskin,et al. Crucial Role of Aldose Reductase Activity and Plasma Glucose Level in Sorbitol Accumulation in Erythrocytes From Diabetic Patients , 1991, Diabetes.
[17] J. Christiansen,et al. Reduction of Glomerular Hyperfiltration in Normoalbuminuric IDDM Patients by 6 mo of Aldose Reductase Inhibition , 1991, Diabetes.
[18] A. Markham,et al. Structure of the human aldose reductase gene. , 1991, The Journal of biological chemistry.
[19] J. Baynes. Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.
[20] T. Akera,et al. Cloning and expression of human aldose reductase. , 1990, The Journal of biological chemistry.
[21] P. Hoffman,et al. Prolonged Aldose Reductase Inhibition in Chronic Peripheral Diabetic Neuropathy: Effects on Microangiopathy , 1990, Diabetic medicine : a journal of the British Diabetic Association.
[22] S. Chung,et al. Cloning and sequence determination of human placental aldose reductase gene. , 1989, The Journal of biological chemistry.
[23] E. Standl,et al. Prevention and Treatment of Diabetic Late Complications , 1989 .
[24] B. Wermuth,et al. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.
[25] C. Nishimura,et al. Depletion of myo‐Inositol and Amino Acids in Galactosemic Neuropathy , 1987, Journal of neurochemistry.
[26] M. Cohen. Aldose reductase, glomerular metabolism, and diabetic nephropathy. , 1986, Metabolism: clinical and experimental.
[27] J. Kinoshita,et al. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. , 1983, Science.
[28] Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.
[29] A. Tjon-A-Tsien,et al. The Efficacy of Aldose Reductase Inhibitors in the Management of Diabetic Complications , 1995 .
[30] H Keen,et al. The Diabetes Control and Complications Trial (DCCT). , 1994, Health trends.
[31] A. Demaine,et al. Polymorphisms of the aldose reductase locus (ALR2) and susceptibility to diabetic microvascular complications. , 1993, Advances in Experimental Medicine and Biology.
[32] A. Krolewski,et al. Epidemiology and clinical impact of diabetic late complications in IDDM , 1989 .
[33] M. Sciadini,et al. Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats. , 1988, Pharmacology.
[34] P. Terasaki,et al. The Data and Statistical Analysis , 1985 .